Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

2.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

3.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

4.

Oncology Drug Shortages Persist, but Continue to Evolve

5.

Are patients with advanced cancer receiving treatment aligned with their goals?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot